Marco Emgenbroich

This inventor holds 13 USPTO granted patents and 18 published patent applications and 10 EPO patents. Top assignees: Lts Lohmann Therapie-Systeme Ag, Ddp Specialty Electronic Materials US 9, LLC, Dow Silicones Corporation. Active years: 2021-2026.

USPTO Granted Patents = 13 (Patent Applications = 18)

% Patents Active = 92.3

EPO Patents = 10 (Patent Applications = 26)

Average Co-Inventor Count = 3.4

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

13 out of 333

Lts Lohmann Therapie-Systeme Ag

patents

3 out of 11

Ddp Specialty Electronic Materials US 9, LLC

patents

2 out of 484

Dow Silicones Corporation

patents

where one patent can have more than one assignee

Years Active: 2021-2026

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12629344 - TTS-formulation with THC (2026-05-19),

2. 12427119 - Transdermal delivery system including an interface mediator (2025-09-30),

3. 12214088 - Transdermal therapeutic system for the transdermal administration of guanfacine comprising at least one additive (2025-02-04),

4. 12168074 - Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer (2024-12-17),

5. 12070521 - Method for adjusting the release of active agent in a transdermal delivery system (2024-08-27),

6. 12048770 - Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone acrylic hybrid polymer (2024-07-30),

7. 11752110 - Transdermal delivery system including an interface mediator (2023-09-12),

8. 11633367 - Transdermal delivery system containing rotigotine (2023-04-25),

9. 11576874 - Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer (2023-02-14),

10. 11426359 - Method for adjusting the release of active agent in a transdermal delivery system (2022-08-30),

11. 11389421 - Transdermal therapeutic system for the transdermal administration of rivastigmine (2022-07-19),

12. 11389410 - Multi-day patch for the transdermal administration of rotigotine (2022-07-19),

13. 11198800 - Control of adhesive domains (2021-12-14),

Title: Marco Emgenbroich: Innovator in Transdermal Delivery Systems

Introduction

Marco Emgenbroich is a notable inventor based in Rheinbach, Germany. He has made significant contributions to the field of transdermal delivery systems, holding a total of 12 patents. His work focuses on innovative methods for the transdermal administration of therapeutic agents.

Latest Patents

Among his latest patents is a transdermal delivery system that includes an interface mediator. This invention relates to a therapeutic system designed for the transdermal administration of a systemically active agent, featuring a self-adhesive layer structure. The system comprises a backing layer and a dried biphasic layer, which includes an outer phase made up of a polymer or polymer mixture and an inner phase containing at least one active agent. The dried biphasic layer also incorporates an interface mediator with specific viscosity characteristics. Another significant patent involves a transdermal therapeutic system for the administration of guanfacine, which includes a guanfacine-containing layer structure and at least one polymer and additive.

Career Highlights

Marco has worked with several prominent companies, including LTS Lohmann Therapie-Systeme AG and DDP Specialty Electronic Materials US 9, LLC. His experience in these organizations has contributed to his expertise in developing advanced therapeutic systems.

Collaborations

He has collaborated with notable coworkers such as Elke Klein and Heike Kluth, further enhancing his innovative projects and research.

Conclusion

Marco Emgenbroich's contributions to transdermal delivery systems exemplify his commitment to innovation in the field. His patents reflect a deep understanding of therapeutic applications and materials science.